Additionally, Bergaggio et al. used lorlatinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor, to boost ALK receptor expression in neuroblastoma tumors, thereby enhancing the effectiveness of ALK.CAR-T therapy [30]. This evidence concerns the gene ALK and neuroblastoma.